Vaio,
Andractim is not a miracle cure, it doesn't work for some people but it DOES work for others!!!!!
This is evidenced in the New England Journal of Medicine by Glenn D Braunstein M.D endocrinologist in his paper entitled gynecomastia.
This is an extract quoted verbatim
The non-aromatizable androgen dihydrotestosterone has been used iether by injection or percutaneously, in a group of patients with prolonged pubertal gynecomastia. Approximately 75% had reductions in breast-tissue volume, with 25% having a complete response.
unquote
If you want me to send you a photocopy of this document simply pm me with your address.
Here are some dynamic before and after photos from this very site
http://www.gynecomastia.org/cgi-bin/gyne_yabb/YaBB.cgi?board=1;action=display;num=1095446135;start=15Furthermore;
Unique Identifier
3088241
Authors
Eberle AJ. Sparrow JT. Keenan BS.
Title
Treatment of persistent pubertal gynecomastia with dihydrotestosterone heptanoate.
Source
Journal of Pediatrics. 109(1):144-9, 1986 Jul.
Abstract
Four boys with persistent pubertal gynecomastia were given intramuscular dihydrotestosterone heptanoate (DHT-hp) at 2 to 4-week intervals for 16 weeks. By the end of treatment, breast size in all four boys had decreased 67% to 78%. Initial plasma levels of gonadotropins, estradiol, testosterone, and dihydrotestosterone (DHT) were normal. Mean plasma DHT concentration rose with the injections of DHT-hp, and remained elevated throughout the treatment period. Estradiol, LH, FSH, and testosterone decreased during treatment, as did 24-hour urinary LH and FSH. No regrowth of breast tissue was observed 6 to 15 months after treatment, although hormone concentrations had returned to near pretreatment values by 2 months after the last injection. DHT-hp has potential to be an effective medical therapy for persistent pubertal gynecomastia.
Unique Identifier
6354523
Authors
Kuhn JM. Roca R. Laudat MH. Rieu M. Luton JP. Bricaire H.
Title
Studies on the treatment of idiopathic gynaecomastia with percutaneous dihydrotestosterone.
Source
Clinical Endocrinology. 19(4):513-20, 1983 Oct.
Abstract
We have studied clinical and endocrine parameters in a group (group A) of forth men referred to us because of persistent idiopathic gynaecomastia (of more than 18 months duration), before and during the administration of percutaneous dihydrotestosterone (DHT). The endocrine parameters (testosterone (T), 17 beta-oestradiol (E2), DHT, gonadotrophins (FSH and LH) and prolactin (PRL), were compared to those of control groups of 12 healthy men on DHT therapy (group B) and 10 on placebo (group C). Local administration of DHT was followed by the complete disappearance of gynaecomastia in 10 patients, partial regression in 19 and no change in 11 patients after 4 to 20 weeks of percutaneous DHT (125 mg twice daily). Before treatment the T + DHT/E2 ratio was significantly (P less than 0.001) lower in group A 244 +/- 21 (SEM) than in groups B and C (361 +/- 21) while T, DHT and E2 concentrations were all within the normal range. During DHT treatment plasma hormone levels were measured in 26 patients from group A: DHT levels increases significantly (day 0: 1.63 +/- 0.14 nmol/l; day 15: 12.8 +/- 1.6 nmol/l, P less than 0.001) while T and E2 levels fell significantly (T: day 0: 22.6 +/- 1.2 nmol/l; day 15: 11.0 +/- 1.5 nmol/l, P less than 0.001; E2: day 0: 110.5 +/- 7.12 pmol/l; day 15: 86.79 +/- 9.4 pmol/l, P less than 0.01). The T/E2 ratio decreased from 231 +/- 20 to 164 +/- 27 (P less than 0.05) while the T + DHT/E2 ratio increased significantly (P less than 0.02) to a normal mean value (day 15: 354 +/- 57).(ABSTRACT TRUNCATED AT 250 WORDS)